FDAnews Device Daily Bulletin

Somahlution Reveals Positive Study Results Showing Efficacy of DuraGraft

Oct. 5, 2016

Somahlution’s DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery, the company said at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting.

DuraGraft treatment for 2,436 patients who underwent CABG surgery has shown statistically significant lower risks for non-fatal myocardial infarction, repeat revascularization, and a composite of all major adverse cardiac events.

DuraGraft is currently not available in the U.S. market. — Cynthia Jessup

View today's stories